Iron chelators induce autophagic cell death in multiple myeloma cells

Leukemia Research

Volumn 38, Issue 8, 2014, Pages 988-996

  Pullarkat, Vinod ^a   Meng, Zhuo ^a   Donohue, Cecile ^b   Yamamoto, Vicky N ^a   Tomassetti, Sarah ^a   Bhatia, Ravi ^b   Krishnan, Amrita ^b   Forman, Stephen J ^b   Synold, Timothy W ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Autophagy; Deferasirox; Deferoxamine; Iron chelation; MTOR; Multiple myeloma; P70S6 kinase

Indexed keywords

DEFERASIROX; DEFEROXAMINE; MAMMALIAN TARGET OF RAPAMYCIN; REACTIVE OXYGEN METABOLITE; S6 KINASE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; BONE MARROW CELL; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EXPOSURE; HUMAN; HUMAN CELL; IRON CHELATION; MULTIPLE MYELOMA; MULTIPLE MYELOMA CELL LINE; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

AUTOPHAGY; DEFERASIROX; DEFEROXAMINE; IRON CHELATION; MTOR; MULTIPLE MYELOMA; P70S6 KINASE;

AUTOPHAGY; BENZOATES; CELL LINE, TUMOR; CELL PROLIFERATION; DEFEROXAMINE; DRUG EVALUATION, PRECLINICAL; HUMANS; IRON CHELATING AGENTS; MULTIPLE MYELOMA; PRIMARY CELL CULTURE; REACTIVE OXYGEN SPECIES; TRIAZOLES;

EID: 84904564859     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.06.005     Document Type: Article

References (32)

1. Yu Y., Kovacevic Z., Richardson D.R. Tuning cell cycle regulation with an iron key. Cell Cycle 2007, 6:1982-1994.
2. Gatter K.C., Brown G., Trowbridge I.S., Woolston R.E., Mason D.Y. Transferrin receptors in human tissues: their distribution and possible clinical relevance. J Clin Pathol 1983, 36:539-545.
3. Richardson D.R., Ponka P. The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. Biochim Biophys Acta 1997, 1331:1-40.
4. Eberhard Y., McDermott S.P., Wang X., et al. Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. Blood 2009, 114:3064-3073.
5. Whitnall M., Howard J., Ponka P., Richardson D.R. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci USA 2006, 103:14901-14906.
6. Jiao Y., Wilkinson J., Di X., et al. Curcumin, a cancer chemopreventive and chemotherapeutic agent is a biologically active iron chelator. Blood 2009, 113:462-469.
7. Yamasaki T., Terai S., Sakaida I. Deferoxamine for advanced hepatocellular carcinoma. N Engl J Med 2011, 365:576-578.
8. Fukushima T., Kawabata H., Nakamura T., et al. Iron chelation therapy with deferasirox induced complete remission in a patient with chemotherapy-resistant acute monocytic leukemia. Anticancer Res 2011, 31:1741-1744.
9. Donfrancesco A., Deb G., Dominici C., Pileggi D., Castello M.A., Helson L. Effects of a single course of deferoxamine in neuroblastoma patients. Cancer Res 1990, 50:4929-4930.
10. Vidulich K., Hanks D., Etzell J.E. Iron in neoplastic cells of plasma cell myeloma. Am J Hematol 2006, 81:216-217.
11. Wulfhekel U., Dullmann J. Storage of iron in bone marrow plasma cells. Acta Haematol 1999, 101:7-15.
12. Brittenham G.M. Iron chelating therapy for transfusional iron overload. N Engl J Med 2011, 364:146-156.
13. Chandra J. Oxidative stress by targeted agents promotes cytotoxicity in hematologic malignancies. Antioxid Redox Signal 2009, 11:1123-1137.
14. Chaston T.B., Watts R.N., Yuan J., Richardson D.R. Potent antitumor activity of novel iron chelators derived from Di-2-pyridylketone isonicotinoyl hydrazone involves Fenton-derived free radical generation. Clin Cancer Res 2004, 10:7365-7374.
15. Callens C., Coulon S., Naudin J., et al. Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia. J Exp Med 2010, 207:731-750.
16. Greenberg P.L., Koller C.A., Cabantchik Z.I., et al. Prospective assessment of effects of iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes. Leuk Res 2010, 34:1560-1565.
17. Pullarkat V., Sehgal A., Li L., et al. Deferasirox exposure induces reactive oxygen species and reduces growth and viability of myelodysplastic hematopoietic progenitors. Leuk Res 2012, 36:966-973.
18. Choi A.M.K., Ryter S.W., Levine B. Autophagy in human health and disease. N Engl J Med 2013, 368:651-652.
19. Ohyashiki J.H., Kobayashi C., Hamamura R., Okabe S., Tauchi T., Ohyashiki K. The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1. Cancer Sci 2009, 100:970-977.
20. Puissant A., Robert G., Auberger P. Targeting autophagy to fight hematologic malignancies. Cell Cycle 2010, 9:3470-3478.
21. Liu E.Y., Ryan K.M. Autophagy and cancer-issues we need to digest. J Cell Sci 2012, 125:2359-2368.
22. Lozy F., Karantza V. Autophagy and cancer cell metabolism. Stem Cell Develop Biol 2012, 23:395-401.
23. Zeng R., He J., Peng J., et al. The time-dependent autophagy protects against apoptosis with possible involvement of Sirt1 protein in multiple myeloma under nutrient depletion. Ann Hematol 2012, 91:407-417.
24. Hoang B., Benavides A., Shi Y., Frost P., Lichtenstein A. Effect of autophagy on multiple myeloma cell viability. Mol Cancer Ther 2009, 8:1974-1984.
25. Periyasamy-Thandavan S., Jackson W.H., Samaddar J.S., et al. Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress and induces caspase-dependent cell death in antiestrogen-senditive and resistant ER+ breast cancer cells. Autophagy 2010, 6:19-35.
26. 1 and extracellular signal-regulated kinase (ERK1/2) inhibition. Blood 2012, 120:3519-3529.
27. Liao A., Hu R., Zhao Q., et al. Autophagy induced by FTY720 promotes apoptosis in U266 cells. Eur J Pharm Sci 2012, 45:600-605.
28. Choi H.N., Jin H.O., Kim J.H., et al. Inhibition of S6K1 enhances glusoce deprivation-induced cell death via downregulation of anti-apoptotic proteins in MCF-7 breast cancer cells. Biochem Biophys Res Commun 2013, 432:123-128.
29. Vaira V., Lee C.W., Goel H.L., Bosari S., Languino L.R., Altieri D.C. Regulation of surviving expression by IGF-1/mTOR signaling. Oncogene 2007, 26:2678-2684.
30. Chen Y., McMillan-Ward Kong J., Israels S.J., Gibson S.B. Oxidative stress induces autophagic cell death independent of apoptosis in transformed and cancer cells. Cell Death Differ 2008, 15:171-182.
31. Messa E., Carturan S., Maffe C., et al. Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. Haematologica 2010, 95:1308-1316.
32. Demchenko Y.N., Kuehl W.M. A critical role for the NFkB pathway in multiple myeloma. Oncotarget 2010, 1:68-69.